Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals
|
|
|
- Lenard Reeves
- 6 years ago
- Views:
Transcription
1 Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals Polina German, Philip S Pang, Steve West, Lingling Han, Karim Sajwani and Anita Mathias Gilead Sciences, Foster City, CA 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2014 Washington, DC
2 Disclosures I am an employee of Gilead Sciences, Inc 2
3 Sofosbuvir (SOF, Formerly GS-7977) HCV NS5B nucleotide analog prodrug with broad genotypic activity Activated by sequential metabolic pathways including Low affinity and high capacity hydrolases (CES1, CatA, HINT1) Nucleotide phosphorylation (UMP-CMP kinase, NDP kinase) SOF enters hepatocytes and is converted to active SOF-TP SOF undergoes extrahepatic metabolism to form GS (predominant inactive circulating metabolite), principally eliminated in urine Safe and well tolerated Once daily dosing Favorable safety profile in preclinical/clinical studies 3
4 Ledipasvir (LDV, Formerly GS-5885) HCV NS5A inhibitor Picomolar potency against GT1a and 1b LDV is minimally metabolized and primarily eliminated in the feces Safe and well tolerated Once daily dosing Favorable safety profile in preclinical/clinical studies LDV/SOF (90/400 mg) fixed-dose combination tablet is under US-EU regulatory review for the treatment of HCV GT 1 infection 4
5 Pre/Clinical Pharmacology LDV and SOF (not GS ) are substrates for P-gp and BCRP LDV but not SOF is an inhibitor of intestinal P-gp and BCRP LDV is an inhibitor of hepatic OATP1B1, 1B3 and BSEP at concentrations exceeding those achieved clinically LDV and SOF are not substrates for hepatic OCT1, OATP1B1 or OATP1B3 GS is not a substrate for renal transporters OAT1, OAT3, or OCT2 LDV and SOF are not substrates for UGT1A1 LDV is subject to slow oxidative metabolism No turnover by CYP450 isozymes (in vitro phenotyping studies) SOF is not a substrate for CYP450 Limited potential for clinically significant drug interactions 5
6 HIV Antiretrovirals Integrase strand transfer inhibitor Raltegravir (RAL, Isentress ) NNRTI-based regimens Efavirenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF) (ATR, Atripla ) Emtricitabine/rilpivirine (RPV)/tenofovir DF (CPA, Complera ) 6
7 Objectives Primary To evaluate the drug-drug interaction between LDV and RAL SOF and RAL may be administered without dose adjustment 1 To evaluate the drug-drug interaction between LDV/SOF and ATR or CPA Secondary To evaluate the safety and tolerability of co-administration of LDV with RAL and LDV/SOF with ATR or CPA 1. Kirby B, et al. AASLD
8 Methods Two Phase 1, open-label, randomized, multiple-dose, cross-over DDIs in healthy male and female subjects Study 1 Fed (N=30) LDV (90 mg QD) + RAL (400 mg BID) Study 2 Cohort 1: Fasted (n=32) LDV/SOF (90/400 mg QD) + ATR (600/200/300 mg QD) Days 1-10 Days Days LDV RAL LDV + RAL LDV LDV + RAL RAL RAL LDV LDV + RAL RAL LDV + RAL LDV LDV + RAL LDV RAL LDV + RAL RAL LDV Days 1-14 Days LDV/SOF LDV/SOF + ATR ATR LDV/SOF + ATR Cohort 2: Fed (n=32) LDV/SOF (90/400 mg QD) + CPA (200/25/300 mg QD) Days 1-10 Days LDV/SOF LDV/SOF + CPA CPA LDV/SOF + CPA 8
9 Methods PK sampling was collected over 24 hours for LDV, SOF, GS , EFV, RPV, FTC and TFV and over 12 hours for RAL Plasma concentrations were determined using validated LC/MS/MS assays PK parameters were estimated using noncompartmental methods (WinNonlin 6.3, Pharsight Corp., USA) Geometric least-squares mean ratios and 90% confidence intervals (Test: Reference) were estimated using ANOVA for AUC tau, C max and C tau and compared against lack of PK alteration boundaries of % Adverse event (AE) monitoring, clinical laboratory, physical examination and ECG evaluations were performed throughout study 9
10 Subject Enrollment and Demographics Subjects Study 1 Study 2 Cohort 1 Cohort 2 Enrolled/completed*, n 30/28 32/29 32/29 Mean age, y (range) 32 (22, 45) 35 (20, 45) 35 (23, 45) Mean weight, kg (range) 80 (56, 101) 77 (57, 102) 75 (50, 99) Sex (male/female), n 23/7 23/9 19/13 Race, n (%) White 23 (77) 26 (81) 20 (63) Non-white 7 (23) 6 (19) 12 (38) Ethnicity n (%) Hispanic/Latino 25 (83) 25 (78) 24 (75) Non-Hispanic/Latino 5 (17) 7 (22) 8 (25) *Study 1: 2 subjects discontinued (DCed) due to adverse events (AE); Study 2 (Cohort 1): 2 subjects withdrew consent; 1 DCed due to AE; Study 2 (Cohort 2): 1 subject withdrew consent; 2 DCed due to AE. 10
11 Safety No Grade 3 (severe) or Grade 4 (life-threatening) AEs or serious AEs Majority of AEs were Grade 1 (mild) AE by System Organ Class, n of subjects (%) Study 1 n=30 Cohort 1 n=32 Study 2 Cohort 2 n=32 Treatment-Emergent AEs 10 (33) 21 (66) 11 (34) AEs leading to discontinuation* 2 (7) 1 (3) 1 (3) Study drug-related AEs 1 (3) 11 (34) 6 (19) Cardiac disorders 1 (3) Gastrointestinal disorders 1 (3) 8 (25) 6 (19) General disorders 1 (3) Musculoskeletal and connective tissue disorders 1 (3) Nervous system disorders 2 (6) Psychiatric disorders 1 (3) 1 (3) Reproductive systemic and breast disorders 1 (3) Skin and subcutaneous tissue disorders 1 (3) *Study 1: Grade 2 abdominal pain; Grade 2 furuncle; Study 2 (Cohort 1): Grade 1 nausea; Study 2 (Cohort 2): Grade 2 atrial fibrillation. 11
12 Effect of RAL on LDV/SOF mean ± SD LDV PK Parameters GMR% (90% CI): LDV + RAL vs LDV AUC tau (ng h/ml) 91.5 (84.0, 99.6) C max (ng/ml) 92.2 (84.9, 100) C tau (ng/ml) 89.1 (81.3, 97.8) Data presented to 3 significant figures; LDV + RAL: n=28; LDV: n=29. No effect of RAL on LDV PK Previous data demonstrated no DDI between SOF and RAL 1 1. Kirby B, et al. AASLD
13 Effect of ATR on LDV/SOF mean ± SD ~ 30% reduction in LDV PK with ATR Not clinically significant based on exposure-response evaluation No impact on SOF or GS PK GMR% (90% CI): LDV/SOF + ATR vs LDV/SOF PK Parameters LDV SOF GS AUC tau (ng h/ml) 66.4 (58.7, 75.3) 94.3 (81.0, 110) 89.6 (82.8, 96.9) C max (ng/ml) 66.4 (58.9, 74.9) 103 (86.7, 123) 85.7 (76.2, 96.3) C tau (ng/ml) 66.1 (57.1, 76.5) 107 (102, 113) Data presented to 3 significant figures; n=14. 13
14 Effect of CPA on LDV/SOF mean ± SD No impact of CPA on LDV, SOF or GS PK GMR% (90% CI): LDV/SOF + CPA vs LDV/SOF PK Parameters LDV SOF GS AUC tau (ng h/ml) 108 (102, 115) 110 (101, 121) 115 (111, 119) C max (ng/ml) 101 (94.6, 107) 105 (92.5, 120) 106 (101, 111) C tau (ng/ml) 116 (108, 125) 118 (113, 123) Data presented to 3 significant figures; LDV/SOF+CPA : N=17; LDV/SOF: N=15. 14
15 Effect of LDV/SOF on RAL RAL PK Parameters GMR% (90% CI) AUC tau (ng h/ml) 84.5 (69.8, 102) C max (ng/ml) 82.2 (66.5, 102) C tau (ng/ml) 115 (90.2, 146) Data presented to 3 significant figures; LDV + RAL: N=28; LDV: N=29. mean ± SD Approximately 15-18% change in RAL PK with LDV Similar or higher decreases in RAL PK with TVR/r and EFV 2,3 Previous data demonstrated no DDI between SOF and RAL 1 1. Kirby B, et al. AASLD 2012; 2. Hanley WD, et al. AAC 2009; 3. Iwamoto M, AAC
16 Effect of LDV/SOF on EFV (ATR) and RPV (CPA) mean ± SD No impact on EFV or RPV PK by LDV/SOF GMR% (90% CI): LDV/SOF + ARV vs ARV PK Parameters EFV RPV AUC tau (ng h/ml) 89.7 (83.9, 95.9) 102 (93.6, 111) C max (ng/ml) 87.7 (78.6, 96.9) 97.0 (87.9, 107) C tau (ng/ml) 90.8 (83.1, 99.1) 112 (103, 121) Data presented to 3 significant figures; LDV/SOF + ATR: n=15; ATR: n=17; LDV/SOF + CPA: n=14; CPA: n=14. 16
17 Effect of LDV/SOF on FTC (ATR or CPA) [FTC] (ng/ml) mean ± SD No impact on FTC PK by LDV/SOF GMR% (90% CI): LDV/SOF + ARV vs ARV FTC PK Parameter ATR CPA AUC tau (ng h/ml) 105 (98.1, 111) 104 (102, 108) C max (ng/ml) 108 (97.0, 121) 102 (97.9, 106) C tau (ng/ml) 103 (98.0, 111) 106 (97.1, 115) Data presented to 3 significant figures; LDV/SOF + ATR: n=15; ATR: n=17; LDV/SOF + CPA: n=14; CPA: n=14. 17
18 Effect of LDV/SOF on TFV (ATR or CPA) mean ± SD Mean (%CV) GMR% (90% CI): LDV/SOF + ARV vs ARV TFV PK Parameter LDV/SOF + ATR LDV/SOF + CPA ATR CPA AUC tau (ng h/ml) 4400 (27.1) 4780 (28.6) 198 (177, 223) 140 (131, 150) C max (ng/ml) 527 (29.9) 490 (24.1) 179 (156, 204) 132 (125, 139) C tau (ng/ml) 113 (33.0) 118 (26.4) 263 (237, 297) 191 (174, 210) Data presented to 3 significant figures; LDV/SOF + ATR: n=15; ATR: n=17; LDV/SOF + CPA: n=14; CPA: n=14. LDV/SOF increased TFV exposure Similar absolute TFV exposures (within ATR or CPA) with LDV/SOF TFV exposures in LDV/SOF + NNRTI-based regimens are similar to those with boosted HIV PIs Lack of marked changes in TFV Cl renal (data on file) 18
19 Conclusions and Next Steps LDV/SOF and RAL, ATR or CPA (or components) may be co-administered without dose adjustment Study treatments were well tolerated ION-4: Phase 3 HIV/HCV co-infection trial of LDV/SOF Allowed HIV ARV regimens: RAL + FTC/TDF; ATR or CPA (or components) Planned/ongoing Phase 1 DDI evaluation of LDV/SOF with ARVs Boosted PI regimens EVG/COBI/FTC/TDF (Stribild ) EVG/COBI/FTC/TAF Dolutegravir 19
20 Acknowledgments We extend our thanks to participants and study team. This study was funded by Gilead Sciences, Inc. 20
Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens Kimberly L. Garrison, Erik Mogalian, Heather Zhang, Grace Ma, Steve
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
Erik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs Erik Mogalian, Polina German, Chris Yang, Lisa
ICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen
Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen Polina German, Maggie Wang, David Warren and Brian Kearney Gilead Sciences Foster City, CA,
Potential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
Slide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015
Slide 1 Will DAA drug interactions matter in the future? David Back University of Liverpool UK David Back University of Liverpool June 2015 Disclosures Honoraria received for Advisory Boards, lectures
HIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford
Case #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals
Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University School of Medicine
Ledipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
Professor David Back
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor David Back University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
Jennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc.
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) Jennifer R
Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014
Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters Timothy Eley 15th HIV/HEPPK Workshop 21 May 2014 Disclosures T Eley is a full time employee and stockholder of Bristol-Myers
Update on Drug Interactions of HIV/HCV Treatment Regimens Jennifer J. Kiser, PharmD
Update on Drug Interactions of HIV/HCV Treatment Regimens Jennifer J. Kiser, PharmD Associate Professor University of Colorado Disclosures Dr. Kiser receives research funding (paid to her institution)
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin S Ramanathan, H Wang, T Stondell, A Cheng, and BP Kearney Gilead Sciences, Inc.,
3/28/2016. The Top 5 Things to Remember about Treating HCV
The Top 5 Things to Remember about Treating HCV Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina FORMATTED: MM/DD/YY New York, New York:
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
Selected Properties of Ledipasvir
Selected Properties of Ledipasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Harvoni (ledipasvir and sofosbuvir), GS-5885 Glilead Ledipasvir prevents replication
Treatment of HCV in HIV/HCV Coinfection
Treatment of HCV in HIV/HCV Coinfection Michael S. Saag, MD Associate Dean, Global Health Professor of Medicine Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
CO-ADMINISTRATION WITH GRAZOPREVIR AND ELBASVIR HAS NO EFFECT ON PRAVASTATIN EXPOSURE BUT INCREASES ROSUVASTATIN EXPOSURE IN HEALTHY SUBJECTS
CO-ADMINISTRATION WITH GRAZOPREVIR AND ELBASVIR HAS NO EFFECT ON PRAVASTATIN EXPOSURE BUT INCREASES ROSUVASTATIN EXPOSURE IN HEALTHY SUBJECTS Luzelena Caro 1, William L. Marshall 1, Hwa-Ping Feng 1, Zifang
Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
Integrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
Preliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Patients with Chronic HCV or HCV/HIV Co-Infection
Preliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Patients with Chronic HCV or HCV/HIV Co-Infection Konstantin Zhdanov 1, Viacheslav Morozov 2, Elena A Orlova-Morozova 3, Riina Salupere
Didactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15
Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine
DRUG-DRUG INTERACTIONS WITH GRAZOPREVIR/ELBASVIR: PRACTICAL CONSIDERATIONS FOR THE CARE OF HIV/HCV CO-INFECTED PATIENTS
DRUG-DRUG INTERACTIONS WITH GRAZOPREVIR/ELBASVIR: PRACTICAL CONSIDERATIONS FOR THE CARE OF HIV/HCV CO-INFECTED PATIENTS Wendy W. Yeh, M.D. on behalf of the Merck HCV Doublet Team Translational Pharmacology/Translational
Pharmacokinetics (PK) of Bictegravir (BIC) in Combination with Polyvalent Cation Containing (PVCC) Antacids and Supplements
Pharmacokinetics (PK) of Bictegravir (BIC) in Combination with Polyvalent Cation Containing (PVCC) Antacids and Supplements A Mathias 1, Justin Lutz 1, SK West 1, D Xiao 1, SK Chuck 1, H Martin 1, S Kabagambe
HIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
Considerations for the management of Hepatitis C in patients with HIV co-infection
Considerations for the management of Hepatitis C in patients with HIV co-infection Marcella Honkonen, PharmD, BCPS Sunday, February 22, 2012 at 10:15 AM AzPA Southwest Clinical Conference JW Marriott,
HIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE
DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE Matthew P. Kosloski, Weihan Zhao, Hong Li, Stanley Subhead Wang, Calibri Joaquin 14pt, Valdes,
Report on the Deliberation Results
Report on the Deliberation Results November 16, 2016 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Vemlidy
What are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
Hepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
Merck Sharp & Dohme Corp., The Netherlands; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; Yale University, New Haven, CT, USA;
Pharmacokinetic Interaction Between HCV Protease Inhibitor Boceprevir and Methadone or Buprenorphine/Naloxone in Subjects on Stable Maintenance Therapy Ellen GJ Hulskotte, 1 Hwa-Ping Feng, 2 R Douglas
GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection John J Faragon, PharmD, BCPS, AAHIV-P Regional Pharmacy Director, NY/NJ AIDS Education and Training Center Pharmacist, HIV Medicine, Albany Medical
Treating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
Pharmacology for all HCV Clinicians
Pharmacology for all HCV Clinicians Disclosure I have nothing to disclose. Parya Saberi, PharmD, MAS Assistant Professor, UCSF Center for AIDS Prevention Studies Medical Management of HIV/AIDS and Hepatitis
Update on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
Why make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
Clinical Notes, management of HIV/HCV patients in real life
HCV TREATMENT: OPEN QUESTIONS Clinical Notes, management of HIV/HCV patients in real life Letizia Marinaro Malattie infettive Ospedale Amedeo Di Savoia, Turin 11 TH RESIDENTIAL COURSE ON CLINICAL PHARMACOLOGY
DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects
Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects MC. Rouan, J. Snoeys, S. Ouwerkerk-Mahadevan, R. Verloes,
Merck & Co., Inc., Kenilworth, NJ. Celerion, Inc., Lincoln, NE
A LINIALLY MEANINGFUL DRUG-DRUG INTERATION OBSERVED BETWEEN ZEPATIER TM (GRAZOPREVIR/ELBASVIR) AND STRIBILD HIV FIXED-DOSE OMBINATION IN HEALTHY SUBJETS Hwa-Ping Feng 1, Luzelena aro 1, Katherine M. Dunnington
Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir
Management of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
Clinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
Hepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF
Hepatitis C in HIV Coinfection Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Disclosures I have received research grant support to UCSF related to HCV from the following: Abbvie
Tough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
HIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
Antiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
Update on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg)
Published on: 3 Jul 2017 HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg) Black Box Warning Risk of Hepatitis B Virus Reactivation in Patients Co-Infected with HCV And HBV Test all patients for
PRODUCT MONOGRAPH. EPCLUSA (sofosbuvir/velpatasvir) tablets 400 mg/100 mg Antiviral Agent
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr (sofosbuvir/velpatasvir) tablets 400 mg/100 mg Antiviral Agent Gilead Sciences Inc. Foster City, CA 94404 USA Date of Preparation: September
6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University Baltimore, Maryland Formatted:05-05-2015
NEW ZEALAND DATA SHEET. HARVONI tablets are orange diamond shaped debossed with GSI on one side and the number 7985 on the other side.
NEW ZEALAND DATA SHEET 1 HARVONI (LEDIPASVIR 90 MG, SOFOSBUVIR 400 MG) TABLETS) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ledipasvir 90 mg and sofosbuvir 400 mg) For full list of excipients, see section
17 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 10, 2016 Washington, DC
MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients Nancy Kim 1 *, Wei Gao 1, Xiaoli Shirley
Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV
Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended
6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
HCV/HIV Coinfection ANTON AND MARGARET FUISZ CHAIR IN MEDICINE. HIV and HCV Share Risk Factors PREVALENCE OF CO-INFECTION BY RISK FACTOR 60%
HCV/HIV Coinfection BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY HIV and HCV Share Risk Factors PREVALENCE
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
PRODUCT MONOGRAPH. EPCLUSA (sofosbuvir/velpatasvir) tablets 400 mg/100 mg Antiviral Agent
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr (sofosbuvir/velpatasvir) tablets 400 mg/100 mg Antiviral Agent Gilead Sciences Inc. Foster City, CA 94404 USA Date of Preparation: April 16,
Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
NEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
Special developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
HCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
Dolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
FDA ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING OCTOBER 25, 2013 BACKGROUND PACKAGE SOFOSBUVIR (GS-7977) FOR NDA FOOD AND DRUG ADMINISTRATION
FDA ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING OCTOBER 25, 2013 BACKGROUND PACKAGE FOR NDA 204671 SOFOSBUVIR (GS-7977) FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION RESEARCH OFFICE OF ANTIMICROBIAL
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
Pharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
Effect of Food on Rilpivirine/Emtricitabine/ Tenofovir Disoproxil Fumarate, an Antiretroviral Single Tablet Regimen for the Treatment of HIV Infection
Pharmacokinetics Effect of Food on Rilpivirine/Emtricitabine/ Tenofovir Disoproxil Fumarate, an Antiretroviral Single Tablet Regimen for the Treatment of HIV Infection The Journal of Clinical Pharmacology
D:A:D: Cumulative Exposure to DRV/r Increase MI Risk
D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*
Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
Management of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
Hepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
Cases: Treatment of Hepatitis C in HIV/HCV Coinfection
Cases: Treatment of Hepatitis C in HIV/HCV Coinfection David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
Challenges. Benefits. Control of viral load in plasma. Drug-drug interactions. Adverse effects/drug toxicities. Delay in HIV drug resistance
Benefits Challenges Control of viral load in plasma Drug-drug interactions Delay in HIV drug resistance Longer life expectancy Adverse effects/drug toxicities Drug resistant HIV strains Raltegravir Structural/pharmacokinetic/pharmacodynamic
Poster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA
Poster O_16 Lack of PK Interaction Between the HCV Protease Inhibitor MK-5172 and Methadone and Buprenorphine/Naloxone in Subjects on Stable Opiate Maintenance Therapy Iain Fraser, 1 Wendy W. Yeh, 1 Christina
Pharmacologic Considerations when using DAAs in Cirrhosis
Pharmacologic Considerations when using DAAs in Cirrhosis Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Denver 1 st International Workshop on the Optimal Use of DAAs in Liver Transplant
Review Report. February 22, 2017 Pharmaceuticals and Medical Devices Agency
Review Report February 22, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical products submitted for marketing approval conducted
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
Examining the Basis of Drug-Drug Interaction (DDI) Labeling Recommendations for Antiviral Approvals from 1998 to 2015
Examining the Basis of Drug-Drug Interaction (DDI) Labeling Recommendations for Antiviral Approvals from 1998 to 2015 Tyler Shugg, PharmD PhD Candidate Department of Pharmacy Practice Purdue University
Management of HIV / HCV Coinfection
Advances in HCV 2015 Albany Medical College & Erie County Medical Center Buffalo, New York 24 June 2015 Management of HIV / HCV Coinfection Norbert Bräu, MD, MBA Prof. of Medicine, Icahn School of Medicine
Section 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
Hepatitis C Virus Management
Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San
Sofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents
Hepatitis C Online PDF created July 12, 2018, 1:44 pm Sofosbuvir (Sovaldi) Table of Contents Sofosbuvir Sovaldi Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost and
Clinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
Eliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR
DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR Pharmacology NS3/4A protease inhibitor NS5A inhibitor Adult Dose Investigational: 100 mg once daily Investigational: 50 mg once daily Being developed as